Clinical Trials Logo

Hepatitis A clinical trials

View clinical trials related to Hepatitis A.

Filter by:

NCT ID: NCT03961828 Completed - Hepatitis C Clinical Trials

Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus

Start date: October 1, 2017
Phase: Phase 4
Study type: Interventional

Patients with transfusion dependent Beta Thalassemia suffer from a high incidence of Hepatitis C infection especially in developed countries as Egypt. In our patients we also found a high correlation between hepatitic C infection and Liver fibrosis. in this study we offer our patients treatment with Direct antiviral drugs and assessed the degree of fibrosis before and after treatment. We tested Hyalornic acid as a predictor of the degree of fibrosis before and after treatment.

NCT ID: NCT03951662 Withdrawn - HIV/AIDS Clinical Trials

Immunology of HIV and Alcoholic Hepatitis

Start date: July 1, 2020
Phase:
Study type: Observational

This is prospective, longitudinal cohort study involving HIV-positive, antiretroviral (ART)-treated, heavy alcohol drinking participants who have and do not have alcoholic hepatitis.

NCT ID: NCT03949764 Active, not recruiting - Hepatitis C Clinical Trials

The Kentucky Viral Hepatitis Treatment Study

KeY Treat
Start date: September 23, 2019
Phase: Phase 4
Study type: Interventional

The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the opioid/hepatitis C (HCV) syndemic. KeY Treat is a clinical research study seeking to determine whether removing barriers (cost, insurance, specialist, abstinence) associated with accessing direct-acting antivirals (DAAs) for the treatment of HCV will impact health in Perry County, Kentucky.

NCT ID: NCT03939013 Completed - Hepatitis C Clinical Trials

Hepatitis C: Community Testing and Treatment (CT2 Study Myanmar)

CT2
Start date: January 30, 2019
Phase: N/A
Study type: Interventional

Implementation-effectiveness hybrid trial assessing acceptability, feasibility and cost-effectiveness of community-based point-of-care testing and treatment for hepatitis C. Utilises Cepheid GeneXpert HCV VL device as diagnostic tool (diagnosis of chronic infection and assessment of treatment outcome) and sofosbuvir/daclatasvir for HCV therapy (local standard of care).

NCT ID: NCT03933384 Recruiting - Hepatitis B Clinical Trials

Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

Start date: August 19, 2019
Phase: Phase 4
Study type: Interventional

To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.

NCT ID: NCT03932513 Terminated - Hepatitis B Clinical Trials

Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

Start date: April 11, 2019
Phase: Phase 2
Study type: Interventional

A single center, open-label, study to evaluate the intra-hepatic effect of inarigivir dose per day and three times per week on immune response and viral markers in virally suppressed patients with chronic hepatitis B infection

NCT ID: NCT03920618 Recruiting - Hepatitis B Clinical Trials

Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF

HBV
Start date: February 1, 2019
Phase: N/A
Study type: Interventional

This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.

NCT ID: NCT03920605 Recruiting - Hepatitis B Clinical Trials

Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis

HBV
Start date: February 1, 2019
Phase: N/A
Study type: Interventional

Compared to nucleoside/nucleotide analogues, peginterferon alfa 2a/2b may has more therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b patients. We design this study to investigate treatment of peginterferon alfa 2a/2b in anti-virus treatment experienced patients with HBV related liver fibrosis.

NCT ID: NCT03919565 Recruiting - Hepatitis B Clinical Trials

Optimized Treatment of Peginterferon Alfa 2a/2b in Anti-virus Treatment Naive Patients With HBV Related Liver Fibrosis

HBV
Start date: February 1, 2019
Phase: N/A
Study type: Interventional

Compared to nucleoside/nucleotide analogues, peginterferon alfa 2a/2b may has more therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b patients. We design this study to investigate treatment of peginterferon alfa 2a/2b in anti-virus treatment naive patients with HBV related liver fibrosis.

NCT ID: NCT03917407 Completed - Alcoholic Hepatitis Clinical Trials

DUR-928 in Patients With Alcoholic Hepatitis

DUR-928/AH
Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

The proposed study is An Open-Label, Dose Escalation Study to Assess the Safety, and Pharmacodynamics (PD) signals of DUR 928 in Patients with AH. DUR-928 will be administered in 100 mL 5% dextrose or 0.9% sodium chloride by slow intravenous infusion over 2 hrs (50mL/h) until entire dose is given at Day 1 and Day 4. If a patient meets the hospital discharge criteria prior to the 2nd dose, the patient will receive only one dose of DUR-928 instead of 2 doses.